MENU
WGO
Back to Top
World Gastroenterology Organisation
World Gastroenterology Organisation
Follow
WGO: Facebook WGO: Twitter
Share

Management of Acute Viral Hepatitis

Level: Clinical Trials: 34 Abstracts

Legend: : Key Development,  : Very Important,  : Important, [no star]: Special Mention

 

Telaprevir for retreatment of HCV infection.
Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, YounossiZ, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R,Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G,Polo R, Picchio G, Beumont M; REALIZE Study Team., N Engl J Med. 2011 Jun 23;364(25):2417-28.

 

Tenofovir improves the outcome in patients with spontaneous reactivation ofhepatitis B presenting as acute-on-chronic liver failure.
Garg H, Sarin SK, Kumar M, Garg V, Sharma BC, Kumar A., Hepatology. 2011 Mar;53(3):774-80. doi: 10.1002/hep.24109. Epub 2011 Feb 3.

 

Efficacy of entecavir in chronic hepatitis B patients with mildly elevatedalanine aminotransferase and biopsy-proven histological damage.
Wu IC, Lai CL, Han SH, Han KH, Gordon SC, Chao YC, Tan CK, Sievert W, TanwandeeT, Xu D, Neo BL, Chang TT., Hepatology. 2010 Apr;51(4):1185-9.

 

Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis Cpatients with advanced fibrosis and cirrhosis.
Bruno S, Shiffman ML, Roberts SK, Gane EJ, Messinger D, Hadziyannis SJ, MarcellinP., Hepatology. 2010 Feb;51(2):388-97.

 

Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and4 patients with slow virologic response.
Ferenci P, Laferl H, Scherzer TM, Maieron A, Hofer H, Stauber R, Gschwantler M, Brunner H, Wenisch C, Bischof M, Strasser M, Datz C, Vogel W, Löschenberger K, Steindl-Munda P; Austrian Hepatitis Study Group., Gastroenterology. 2010 Feb;138(2):503-12, 512.e1. Epub 2009 Nov 10.

 

Entecavir treatment for up to 5 years in patients with hepatitis B eantigen-positive chronic hepatitis B.
Chang TT, Lai CL, Kew Yoon S, Lee SS, Coelho HS, Carrilho FJ, Poordad F, Halota W, Horsmans Y, Tsai N, Zhang H, Tenney DJ, Tamez R, Iloeje U., Hepatology. 2010 Feb;51(2):422-30.

 

Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2bplus ribavirin for treating chronic hepatitis C virus infection.
Ascione A, De Luca M, Tartaglione MT, Lampasi F, Di Costanzo GG, Lanza AG, Picciotto FP, Marino-Marsilia G, Fontanella L, Leandro G., Gastroenterology. 2010 Jan;138(1):116-22. Epub 2009 Oct 20.

 

Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2bplus ribavirin in chronic hepatitis C.
Rumi MG, Aghemo A, Prati GM, D'Ambrosio R, Donato MF, Soffredini R, Del Ninno E, Russo A, Colombo M., Gastroenterology. 2010 Jan;138(1):108-15. Epub 2009 Sep 18.

 

Impact of hepatitis C virus infection on the risk of infectious complicationsafter kidney transplantation: data from the RESITRA/REIPI cohort.
López-Medrano F, Fernández-Ruiz M, Morales JM, San-Juan R, Cervera C, CarrataláJ, Torre-Cisneros J, Gavaldá J, Muñoz P, Len O, Martín-Dávila P, Ramos A, MontejoM, Lumbreras C, Moreno A, Aguado JM; Spanish Network for the Research of Infection in Transplantation/Network of Research in Infectious Diseases (RESITRA/REIPI) Study Group., Transplantation. 2011 Sep 15;92(5):543-9.

 

A randomized controlled trial of lamivudine to treat acute hepatitis B.
M Kumar, S Satapathy, R Monga, K Das, S Hissar, C Pande, BC Sharma, SK Sarin, Hepatology. 2007 Jan:97-101

 

Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks.
Sherman M, Yurdaydin C, Simsek H, Silva M, Liaw YF, Rustgi VK, Sette H, Tsai N, Tenney DJ, Vaughan J, Kreter B, Hindes R, AI463026 Benefits of Entecavir for Hepatitis B Liver Disease (BEHoLD) Study Group, Hepatology. 2008 Jul;48(1):99-108

 

Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response.
SM Kamal, AE Fouly, RR Kamel, B Hockenjos, A Al Tawil, KE Khalifa, Q He, MJ Koziel, KM El Naggar, J Rasenack, NH Afdhal, Gastroenterology. 2006 Mar:632-8

 

Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthyvolunteers and hepatitis C patients.
Reesink HW, Fanning GC, Farha KA, Weegink C, Van Vliet A, Van 't Klooster G, LenzO, Aharchi F, Mariën K, Van Remoortere P, de Kock H, Broeckaert F, Meyvisch P,Van Beirendonck E, Simmen K, Verloes R., Gastroenterology. 2010 Mar;138(3):913-21. Epub 2009 Oct 21.

 

Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response totherapy in chronic hepatitis C.
Askarieh G, Alsiö A, Pugnale P, Negro F, Ferrari C, Neumann AU, Pawlotsky JM,Schalm SW, Zeuzem S, Norkrans G, Westin J, Söderholm J, Hellstrand K, Lagging M; DITTO-HCV and NORDynamIC Study Groups., Hepatology. 2010 May;51(5):1523-30.

 

Telaprevir for previously treated chronic HCV infection.
McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, HeathcoteEJ, Zeuzem S, Reesink HW, Garg J, Bsharat M, George S, Kauffman RS, Adda N, DiBisceglie AM; PROVE3 Study Team., N Engl J Med. 2010 Apr 8;362(14):1292-303.

 

Farglitazar lacks antifibrotic activity in patients with chronic hepatitis Cinfection.
McHutchison J, Goodman Z, Patel K, Makhlouf H, Rodriguez-Torres M, Shiffman M,Rockey D, Husa P, Chuang WL, Levine R, Jonas M, Theodore D, Brigandi R, WebsterA, Schultz M, Watson H, Stancil B, Gardner S; Farglitizar Study Investigators., Gastroenterology. 2010 Apr;138(4):1365-73, 1373.e1-2. Epub 2010 Feb 13.

 

Antiviral activity and safety of LB80380 in hepatitis B e antigen-positivechronic hepatitis B patients with lamivudine-resistant disease.
Yuen MF, Han KH, Um SH, Yoon SK, Kim HR, Kim J, Kim CR, Lai CL., Hepatology. 2010 Mar;51(3):767-76.

 

Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antivirallong-term treatment against cirrhosis trial.
Everhart JE, Wright EC, Goodman ZD, Dienstag JL, Hoefs JC, Kleiner DE, Ghany MG, Mills AS, Nash SR, Govindarajan S, Rogers TE, Greenson JK, Brunt EM, BonkovskyHL, Morishima C, Litman HJ; HALT-C Trial Group., Hepatology. 2010 Feb;51(2):585-94.

 

Factors associated with rapid and early virologic response to peginterferonalfa-2a/ribavirin treatment in HCV genotype 1 patients representative of thegeneral chronic hepatitis C population.
Rodriguez-Torres M, Sulkowski MS, Chung RT, Hamzeh FM, Jensen DM., J Viral Hepat. 2010 Feb 1;17(2):139-47. Epub 2009 Aug 5.

 

Loss of HBsAg antigen during treatment with entecavir or lamivudine innucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
Gish RG, Chang TT, Lai CL, de Man R, Gadano A, Poordad F, Yang J, Brett-Smith H, Tamez R., J Viral Hepat. 2010 Jan;17(1):16-22. Epub 2009 Jul 19.

 

Predicting clinical and histologic outcomes based on standard laboratory tests inadvanced chronic hepatitis C.
Ghany MG, Lok AS, Everhart JE, Everson GT, Lee WM, Curto TM, Wright EC, Stoddard AM, Sterling RK, Di Bisceglie AM, Bonkovsky HL, Morishima C, Morgan TR, Dienstag JL; HALT-C Trial Group., Gastroenterology. 2010 Jan;138(1):136-46. Epub 2009 Sep 18.

 

Induction pegylated interferon alfa-2b in combination with ribavirin in patients with genotypes 1 and 4 chronic hepatitis C: a prospective, randomized,multicenter, open-label study.
Brady DE, Torres DM, An JW, Ward JA, Lawitz E, Harrison SA., Clin Gastroenterol Hepatol. 2010 Jan;8(1):66-71.e1. Epub 2009 Sep 10.

 

Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up.
Corey KE, Kane E, Munroe C, Barlow LL, Zheng H, Chung RT, Hepatology. 2009 Oct;50(4):1030-7

 

Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial.
Roberts SK, Weltman MD, Crawford DH, McCaughan GW, Sievert W, Cheng WS, Rawlinson W, Desmond PV, Marks PS, Yoshihara M, Rizkalla B, Depamphilis JK, Dore GJ, Chariot Study Group, Hepatology. 2009 Oct;50(4):1045-55

 

Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone.
Shim JH, Suh DJ, Kim KM, Lim YS, Lee HC, Chung YH, Lee YS, Hepatology. 2009 Oct;50(4):1064-71

 

Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C.
John-Baptiste AA, Tomlinson G, Hsu PC, Krajden M, Heathcote EJ, Laporte A, Yoshida EM, Anderson FH, Krahn MD, Am J Gastroenterol. 2009 Oct;104(10):2439-48

 

Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin.
Reau N, Hadziyannis SJ, Messinger D, Fried MW, Jensen DM, Am J Gastroenterol. 2008 Aug;103(8):1981-8 Cat:

 

A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial.
Hsu C, Hsiung CA, Su IJ, Hwang WS, Wang MC, Lin SF, Lin TH, Hsiao HH, Young JH, Chang MC, Liao YM, Li CC, Wu HB, Tien HF, Chao TY, Liu TW, Cheng AL, Chen PJ, Hepatology. 2008 Mar;47(3):844-53

 

Duration of peginterferon therapy in acute hepatitis C: a randomized trial.
SM Kamal, KN Moustafa, J Chen, J Fehr, A Abdel Moneim, KE Khalifa, LA El Gohary, AH Ramy, MA Madwar, J Rasenack, NH Afdhal, Hepatology. 2006 May:923-31

 

Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.
Yu ML, Dai CY, Huang JF, Chiu CF, Yang YH, Hou NJ, Lee LP, Hsieh MY, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Chuang WL, Hepatology. 2008 Jun;47(6):1884-93

 

Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin inurban minority patients.
Feuerstadt P, Bunim AL, Garcia H, Karlitz JJ, Massoumi H, Thosani AJ, Pellecchia A, Wolkoff AW, Gaglio PJ, Reinus JF., Hepatology. 2010 Apr;51(4):1137-43.

 

The impact of diet on liver fibrosis and on response to interferon therapy in patients with HCV-related chronic hepatitis.
Loguercio C, Federico A, Masarone M, Torella R, Blanco Cdel V, Persico M, Am J Gastroenterol. 2008 Dec;103(12):3159-66 Cat:

 

Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection.
von Wagner M, Hofmann WP, Teuber G, Berg T, Goeser T, Spengler U, Hinrichsen H, Weidenbach H, Gerken G, Manns M, Buggisch P, Herrmann E, Zeuzem S, Hepatology. 2008 Nov;48(5):1404-11 Cat:

 

Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy.
Ferenci P, Scherzer TM, Kerschner H, Rutter K, Beinhardt S, Hofer H, Schöniger-Hekele M, Holzmann H, Steindl-Munda P, Gastroenterology. 2008 Nov;135(5):1561-7